PMN.TO - ProMIS Neurosciences Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.1300
0.0000 (0.00%)
At close: 3:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.1300
Open0.1350
Bid0.1300 x 0
Ask0.1350 x 0
Day's Range0.1300 - 0.1350
52 Week Range0.1000 - 0.3000
Volume41,892
Avg. Volume216,548
Market Cap36.621M
Beta (5Y Monthly)0.27
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateMar. 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
  • GlobeNewswire

    Journal of the American Academy of Neurology Publishes ProMIS Neurosciences’ Abstracts on Novel Antibody Candidates

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers of proteins implicated in the development of neurodegenerative diseases, announced today that the journal Neurology will publish AAN abstracts of data that demonstrate the strength of its antibody programs for Parkinson’s disease/alpha-synuclein (a-syn) and amyotrophic lateral sclerosis (ALS)/TDP-43. The data will appear in the April 14 online supplement to Neurology, the most widely read, highly cited peer-reviewed neurology journal.

  • Baystreet

    Stocks in play: ProMIS Neurosciences, Inc.

    Announced today that the Alzheimer’s Association International Conference® (AAIC®) has accepted several ...

  • GlobeNewswire

    ProMIS Neurosciences to Present Data and Moderate Session at AAIC 2020

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that the Alzheimer’s Association International Conference® (AAIC®) has accepted several abstracts for the company’s Alzheimer’s disease (AD) program. The AAIC also invited ProMIS Chief Development Officer Dr. Johanne Kaplan to chair a session on novel immunotherapeutic approaches for the treatment of AD.

  • GlobeNewswire

    PROMIS NEUROSCIENCES ANNOUNCES APPROVAL FOR WARRANT REPRICING

    ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (PMN.TO) (ARFXF) announces that the Company has received approval from the Toronto Stock Exchange to amend the exercise price of an aggregate of 44,182,530 outstanding common share purchase warrants (the “Warrants”) that were previously issued on August 9, 2017, August 28, 2017, October 30, 2017, April 30, 2018, January 22, 2019, June 26, 2019, November 15, 2019, and December 30, 2019 (the “Warrant Repricing”). Outstanding Warrants currently held by Insiders of the Company will be excluded from the Warrant Repricing. The exercise price of the Warrants is being repriced to CDN $0.13 (USA $0.09) per share, effective April 8, 2020 until May 22, 2020 (the “Warrant Repricing Period”).

  • GlobeNewswire

    ProMIS Neurosciences Announces Fiscal Year 2019 Annual Results

    “Over the course of the past year, the value of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities across multiple neurodegenerative diseases,” stated Eugene Williams, ProMIS’ Executive Chairman.

  • GlobeNewswire

    ProMIS Neurosciences Initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pilot longitudinal study to assess the level of blood-based biomarkers in early AD with the support of Parexel, one of the world’s leading global clinical research organizations (CROs). ProMIS will leverage Parexel’s significant data management and central nervous system (CNS) expertise for the study, which it will use as the historical control arm for its anticipated Phase 1 study of PMN310, a novel antibody that selectively targets the toxic oligomeric species of amyloid beta, a root cause of AD.

  • GlobeNewswire

    ProMIS Neurosciences Announces Gross Proceeds of $1,257,970 Related to the Exercise of Common Stock Warrants

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to report that a total of 6,289,851 of the common share purchase warrants issued on February 10 and February 21, 2017 in a non-brokered private placement were exercised at a price of $0.20 per share for gross proceeds of $1,257,970, the vast majority of such proceeds having been received in the last month prior to the February 21, 2020 expiry date.

  • GlobeNewswire

    ProMIS Neurosciences to Participate in Noble Capital Markets 16th Annual Investor Conference

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in Noble Capital Markets 16th Annual Investor Conference being held at the Hard Rock Hotel in Hollywood, Florida February 16-18, 2020. ProMIS’ Executive Chairman, Eugene Williams will provide an update on the company and present supportive data for the Company’s antibody programs targeting neurodegenerative diseases.

  • Is ProMIS Neurosciences, Inc. (TSE:PMN) Overpaying Its CEO?
    Simply Wall St.

    Is ProMIS Neurosciences, Inc. (TSE:PMN) Overpaying Its CEO?

    Elliot Goldstein has been the CEO of ProMIS Neurosciences, Inc. (TSE:PMN) since 2015. This analysis aims first to...

  • GlobeNewswire

    ProMIS Neurosciences to Participate in the BIO CEO & Investor Conference

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation in the BIO CEO & Investor Conference being held at the Marriott Marquis in New York, February 10-11, 2020. ProMIS’ Executive Chairman, Eugene Williams will provide a brief update on the company and present supportive data for the Company’s antibody programs targeting neurodegenerative diseases.

  • GlobeNewswire

    ProMIS Neurosciences Data for Alzheimer’s Disease Program Targeting Tau Accepted for Presentation at Tau2020

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that data supporting its Alzheimer’s disease program targeting neurotoxic tau has been accepted for presentation at Tau2020 Global Conference, an international conference sponsored by the Alzheimer’s Association, Rainwater Foundation and CurePSP. ProMIS will present data showing the ability of its novel antibody candidates to bind and neutralize the seeding activity of toxic tau species, which—along with the protein amyloid-beta—are considered the most promising targets for potential Alzheimer’s disease (AD) therapy.

  • GlobeNewswire

    ProMIS Neurosciences Appoints Dr. José Luis Molinuevo to its Scientific Advisory Board

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, has welcomed José Luis Molinuevo, MD, PhD,  to its scientific advisory board (SAB). Dr. Molinuevo is an internationally recognized neurologist, researcher, professor, principal investigator and clinician focused on Alzheimer’s disease (AD) and related disorders, including other protein misfolding diseases such as Parkinson’s.

  • GlobeNewswire

    ProMIS Neurosciences to present at Sachs 3rd Annual Neuroscience Innovation Forum

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its participation in the Sachs 3rd Annual Neuroscience Innovation Forum being held on January 12, 2020 at the Marine’s Memorial Club, San Francisco, CA.

  • GlobeNewswire

    ProMIS Neurosciences issues Chairman’s Update detailing positive outlook for Alzheimer’s disease therapy, pipeline in 2020

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairman’s Update, which discusses the outlook for the company’s pipeline in light of anticipated regulatory approval for the first disease modifying therapy for Alzheimer’s disease (AD). Accumulating data continue to validate the need for a drug candidate with improved selectivity for amyloid-beta oligomers (AßO). Compared to Aß-directed antibodies in development, ProMIS’ lead therapeutic antibody candidate, PMN310 demonstrates superior selectivity for toxic AßOs, and great potential as a next-generation, disease-modifying therapy candidate for AD.

  • GlobeNewswire

    ProMIS Neurosciences Completes Second Closing of Private Placement

    ProMIS Neurosciences, Inc. (“ProMIS” or the “Company”) (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases is pleased to announce that further to its news releases dated November 13, 2019 and November 18, 2019, it completed, on December 31, 2019 the second closing of its private placement. In the second closing, the Company issued 3,724,998 units (each a “Unit”) for gross proceeds of approximately CDN$745,000.

  • GlobeNewswire

    ProMIS Neurosciences’ Alzheimer’s disease program takes on renewed significance following positive aducanumab news

    TORONTO and CAMBRIDGE, Mass., Dec. 10, 2019 -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of.

  • Are Insiders Buying ProMIS Neurosciences, Inc. (TSE:PMN) Stock?
    Simply Wall St.

    Are Insiders Buying ProMIS Neurosciences, Inc. (TSE:PMN) Stock?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Aducanumab is good; next generation Alzheimer’s disease therapies will be better

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, commends Biogen for its trailblazing efforts to advance aducanumab. Data released today at CTAD (Clinical Trials on Alzheimer’s Disease conference) strengthen aducanumab’s potential to become the first disease-modifying therapy for Alzheimer’s disease.

  • GlobeNewswire

    ProMIS Neurosciences Completes First Closing of Private Placement

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics  targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce that, further to its news release dated November 13, 2019, it completed on November 15, 2019, the first closing of its private placement of up to $6.5M. In the first closing, the Company issued 10,276,666 Units for gross proceeds of approximately CDN$2,055,333. "We are pleased to announce this first closing and given the interest expressed look forward to the final closing in the coming weeks,” stated Dr. Elliot Goldstein, ProMIS President and CEO.

  • GlobeNewswire

    ProMIS Neurosciences Announces Third Quarter 2019 Results

    ProMIS Neurosciences, Inc. (PMN.TO) (ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced its operational and financial results for the three and nine months ended September 30, 2019. “Over the course of 2019, the breadth and depth of our unique discovery and development platform was further evidenced as ProMIS made considerable progress in expanding its portfolio of opportunities in neurodegenerative diseases,” stated Dr. Elliot Goldstein, ProMIS President and CEO.